Scorpion Capital (@ScorpionFund) Posts On X "We remain short $TWST Twist Bioscience with strong conviction that it is a zero. Detailed thoughts on Monday. We're doing a fresh, intensive round of research which we may publish as a follow up to our Nov 2022 short report..."
Portfolio Pulse from Benzinga Newsdesk
Scorpion Capital has reiterated its short position on Twist Bioscience (TWST), expressing strong conviction that the stock is worthless. They plan to release detailed thoughts and possibly a follow-up report to their November 2022 short report.
August 02, 2024 | 4:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Scorpion Capital has reiterated its short position on Twist Bioscience, expressing strong conviction that the stock is worthless. They plan to release detailed thoughts and possibly a follow-up report to their November 2022 short report.
Scorpion Capital's reiteration of their short position and strong language suggesting the stock is worthless is likely to negatively impact investor sentiment and the stock price of Twist Bioscience in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100